Idorsia announces
financial results for the
first nine months of 2023
The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension
| Event | When |
|
Swiss EQ Technology & Innovation Days |
November 14-16, 2023 |
|
Full-Year 2023 Financial Results reporting* |
February 6, 2024 |
|
Annual General Meeting of Shareholders |
April 11, 2024 |
|
First Quarter 2024 Financial Results reporting* |
April 25, 2024 |
|
Half-Year 2024 Financial Results reporting* |
July 25, 2024 |
*We will be in a silent period for 10 days ahead of the financial reporting.
| 03 Nov 2023 | |
| 24 Oct 2023 | |
| 23 Oct 2023 |
Idorsia published its Nine-Month Financial Reporting 2023 on Tuesday October 24, 2023. An investor conference call and webcast will be held to discuss the results on the same day at 15:00 CEST.
Idorsia published its half year financial results 2023 on Tuesday July 25, 2023.
Idorsia published its first quarter financial results 2023 on Tuesday April 25, 2023.
Idorsia published its full year financial results 2022 on Tuesday February 7, 2023.
Jean-Paul Clozel, CEO of Idorsia, presented at the 41st J.P. Morgan Healthcare Conference 2023.
In December 2022, Idorsia announced that the first patient has entered screening to participate in OPUS, a Phase 3 program to investigate the efficacy and safety of cenerimod, Idorsia’s novel, highly selective S1P1 receptor modulator, as an oral treatment for adult patients with moderate to severe systemic lupus erythematosus.
In November 2022, Idorsia announced the publication of “A randomized controlled trial of the dual endothelin antagonist aprocitentan for resistant hypertension” in The Lancet.
Idorsia published its financial results for the first nine months of 2022 on Tuesday October 25, 2022.
Idorsia published its half year financial results 2022 on Tuesday
July 26, 2022.
In January 2022, Idorsia announced the publication of "Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials" in The Lancet Neurology.
In June 2021, Idorsia announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia’s P2Y12 receptor antagonist, in suspected acute myocardial infarction (AMI).
The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.
Idorsia offers an electronic ‘Stay informed’ service. You will get the news sent to you.
